- Home
- FTHM vs OTLK Comparison
FTHM vs OTLK Comparison
Compare FTHM & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTHM | OTLK |
|---|---|---|
| Founded | 2010 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.5M | 29.2M |
| IPO Year | 2020 | 2016 |
Fundamental Metrics
Financial Performance| Metric | FTHM | OTLK |
|---|---|---|
| Price | $0.91 | $0.26 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $2.50 | $2.50 |
| AVG Volume (30 Days) | 162.1K | ★ 4.7M |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 32.71 | ★ 55.91 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $420,477,000.00 | $8,146,123.00 |
| Revenue This Year | $11.67 | $1,430.98 |
| Revenue Next Year | N/A | $173.23 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.45 | N/A |
| 52 Week Low | $0.48 | $0.16 |
| 52 Week High | $3.37 | $3.39 |
Technical Indicators
Market Signals| Indicator | FTHM | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 51.79 | 45.63 |
| Support Level | $0.89 | $0.17 |
| Resistance Level | $1.50 | $0.29 |
| Average True Range (ATR) | 0.09 | 0.04 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 24.58 | 13.00 |
Price Performance
Historical ComparisonAbout FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, insurance, and Software as a Service (SaaS) offering to brokerages and agents by leveraging proprietary cloud-based software, intelliAgent. The company has three reportable segments namely Real Estate Brokerage, Mortgage and Technology. The brands of the company include Fathom Realty, Dagley Insurance, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. Majority of revenue is from Real Estate segment.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.